The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Within six months, the drug reduced the risk of cardiovascular death by 50% and cut the risk of needing urgent treatment due ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

President Trump shared a story about a businessman friend's frustration with the high cost of a weight-loss drug in the U.S.

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

The National Institute for Health and Care Excellence (Nice) previously stopped its appraisal of semaglutide (Wegovy) for use ...

The Royal College of GPs’ weight loss expert has sounded a warning bell for users of popular drugs Ozempic, Mounjaro and ...